Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xinyan Wu
Institution:
Mayo Clinic
Observed institution:
Mayo Clinic
ORCID:
0000-0002-7745-1614
Observed ORCID:
0000-0002-7745-1614
OpenAlex ID:
A5122997785
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer
2026
·
Julie R. Duffield
, Xiaonan Hou
, et al.
·
Science Translational Medicine
·
4
BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer
2026
·
Annapoorna Venkatachalam
, Annabella R. Strathman
, et al.
·
Signal Transduction and Targeted Therapy
PDF
Show more works
View as search
Works count:
2
Citation count:
4
H-index:
1
I10-index:
Year
Topic
Type
